



Company Overview

iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform.

The iBio Technology platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines.

iBio to Advance COVID-19 LickM-Subunit Vaccine Candidate, IBIO-201

Sep 9 2020, 8:45 AM EDT

iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic

Aug 28 2020, 7:15 AM EDT

iBio Provides Update on IBIO-201 COVID-19 Vaccine Program

Aug 10 2020, 7:15 AM EDT

Stock Overview

Symbol	IBIO
Exchange	NYSE American
Market Cap	362.78m
Last Price	\$2.08
52-Week	\$0.05 - \$7.45

09/25/2020 04:00 PM EDT

Investor Relations

Stephen Kilmer
T: 646-274-3580
skilmer@ibioinc.com

Management Team

Thomas F. Isett

Chief Executive Officer & Chairman of the Board

Robert L. Erwin

President

iBio Inc.

600 Madison Avenue
Suite 1601
New York, NY 10022

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.